摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

naltrexone benzoic acid | 152659-56-8

中文名称
——
中文别名
——
英文名称
naltrexone benzoic acid
英文别名
naltrexone benzoate;naltrexone*PhCO2H;naltrexone benzoic acid salt;(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;benzoic acid
naltrexone benzoic acid化学式
CAS
152659-56-8
化学式
C7H6O2*C20H23NO4
mdl
——
分子量
463.53
InChiKey
PYPGODGSWLKHEV-ITLPAZOVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.91
  • 重原子数:
    34
  • 可旋转键数:
    3
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    107
  • 氢给体数:
    3
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851
    作者:Satoshi Sakami、Koji Kawai、Masayuki Maeda、Takumi Aoki、Hideaki Fujii、Hiroshi Ohno、Tsuyoshi Ito、Akiyoshi Saitoh、Kaoru Nakao、Naoki Izumimoto、Hirotoshi Matsuura、Takashi Endo、Shinya Ueno、Kazuto Natsume、Hiroshi Nagase
    DOI:10.1016/j.bmc.2008.07.065
    日期:2008.9
    oxy-4'H-pyrrolo[3,2,1-ij]quinolino[2',1':6,7]morphinan-14-ol(1b) methanesulfonate (TRK-850), a selective delta opioid receptor antagonist which markedly reduced the number of coughs in a rat cough model. We designed TRK-850 based on naltrindole (NTI), a typical delta opioid receptor antagonist, to improve its permeability through the blood-brain barrier by introducing hydrophobic moieties to NTI. The
    先前我们已经报道过(5R,9R,13S,14S)-17-环丙基甲基-6,7-二-4,5-环-5',6'-二-3-甲基基-4'H的镇咳作用-pyrrolo [3,2,1-ij] quinolino [2',1':6,7]吗啡喃-14-ol(1b)甲磺酸盐(TRK-850),一种选择性的δ阿片受体拮抗剂,可显着减少大鼠咳嗽模型中的咳嗽。我们设计了基于纳曲酮NTI)(一种典型的阿片类阿片受体拮抗剂)的TRK-850,以通过将疏性部分引入NTI来提高其通过血脑屏障的通透性。腹膜内注射的NTI和化合物1b的ED(50)值分别为104微克/千克和2.07微克/千克。止咳药效力的提高可能是由于化合物1b的脑暴露改善所致。但是,1b对细胞色素P450的代谢极为不稳定。
  • Indole derivatives and use thereof in medicines
    申请人:——
    公开号:US20040019071A1
    公开(公告)日:2004-01-29
    This invention relates to: an indole derivative or a pharmaceutically acceptable salt thereof represented by formula (I): 1 wherein R 1 is, for example, hydrogen or C 1-5 alkyl; R 2 is, for example, hydrogen or hydroxy; R 3 is, for example, hydrogen or hydroxy; -Z- is a crosslinkage having 2 to 5 carbon atoms; m is an integer from 0 to 3; n is an integer from 0 to 10; R 4 and R 5 are, for example, fluoro or hydroxy; R 9 is, for example, hydrogen or C 1-5 alkyl; and R 10 and R 11 are bound to each other to form, for example, —O—; and a pharmaceutical composition comprising the same, particularly a drug acting on &dgr; opioid receptor.
    这项发明涉及:由式(I)表示的吲哚生物或其药用可接受的盐:其中R1是,例如,或C1-5烷基;R2是,例如,或羟基;R3是,例如,或羟基;-Z-是具有2到5个原子的交联物;m是从0到3的整数;n是从0到10的整数;R4和R5是,例如,或羟基;R9是,例如,或C1-5烷基;而R10和R11相互结合形成,例如,—O—;以及包含该物质的药物组合物,特别是作用于δ阿片受体的药物。
  • Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives
    作者:Noriki Kutsumura、Yasuaki Koyama、Yasuyuki Nagumo、Ryo Nakajima、Yoshiyuki Miyata、Naoshi Yamamoto、Tsuyoshi Saitoh、Naoko Yoshida、Satoshi Iwata、Hiroshi Nagase
    DOI:10.1016/j.bmc.2017.06.026
    日期:2017.8
    The 7-benzylidenenaltrexone (BNTX) derivatives 2a–v, 3a–c, 13a–c, and 14a were synthesized from naltrexone (1) and evaluated for their antitrichomonal activity. The structure-activity-relationship studies found that 4-iodo-BNTX (2g) showed the highest activity (IC50 = 10.5 µM) and the affinity for the opioid receptor was less important for antitrichomonal activity against Trichomonas vaginalis. The
    纳曲酮(1)合成了7-亚苄基纳曲酮(BNTX)衍生物2a–v,3a–c,13a–c和14a,并评估了其抗滴虫活性。结构-活性-关系研究发现,4--BNTX(2g)表现出最高的活性(IC 50  = 10.5 µM),对阿片样物质受体的亲和力对阴道毛滴虫的抗滴虫活性的重要性较小。。带有迈克尔受体双键和羟基的吗啡喃骨架将是开发抗滴虫剂的特定模板。此外,BNTX衍生物的抗滴虫活性机制可能与标准药物甲硝唑不同。
  • Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
    申请人:Izumimoto Naoki
    公开号:US20060040970A1
    公开(公告)日:2006-02-23
    The invention provides a morphinan derivative of the Formula (I): (wherein R 1 is methyl, cyclopropylmethyl or the like; R 2 and R 3 are hydroxy, methoxy, acetoxy or the like; both Y and Z are valence bonds, —C(═O)— or the like; X is C 2 -C 5 carbon chain (one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen) constituting a part of the ring structure, or the like; (R 4 ) k is substituted or non-substituted benzene fused ring, carbonyl group or the like; R 9 is hydrogen or the like; R 10 and R 11 are bound to represent —O—, or the like, and R 6 is hydrogen or the like) or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a therapeutic or prophylactic agent for urinary frequency or urinary incontinence, comprising as an effective ingredient the morphinan derivative or the pharmaceutically acceptable acid addition salt thereof; a method for therapy or prophylaxis of the diseases.
    该发明提供了一种公式(I)的吗啡类衍生物: 其中,R1为甲基、环丙甲基或类似物;R2和R3分别为羟基、甲基、乙酰基或类似物;Y和Z均为价键、-C(═O)-或类似物;X为C2-C5链(其中一个原子可以被取代)构成环结构的一部分或类似物;(R4)k为取代或非取代融合环、羰基基团或类似物;R9为或类似物;R10和R11被结合表示为-O-或类似物,R6为或类似物,或其药学上可接受的酸加成盐。该发明还提供了一种治疗或预防尿频或尿失禁的药物,其有效成分为吗啡类衍生物或其药学上可接受的酸加成盐;以及治疗或预防该疾病的方法。
  • MORPHINAN DERIVATIVE AND MEDICINAL USE
    申请人:TORAY INDUSTRIES, INC.
    公开号:EP0577847A1
    公开(公告)日:1994-01-12
    A morphinan derivative represented by general formula (1) or a pharmacologically acceptable acid addition salt thereof, an analgesic and diuretic containing the same as the active ingredient, and a process for producing the same The invention compound has potent analgesic and diuretic activities as a highly selective κ-opioid agonist, thus being useful as an analgesic and diuretic.
    一种由通式(1)代表的吗啡南衍生物或其药理上可接受的酸加成盐,一种含有吗啡南衍生物作为活性成分的镇痛剂和利尿剂,以及生产吗啡南衍生物的工艺。 本发明化合物作为一种高选择性κ-阿片激动剂,具有强效的镇痛和利尿活性,因此可用作镇痛剂和利尿剂。
查看更多